FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998504732> ?p ?o ?g. }

• W1998504732 endingPage "114" @default.
• W1998504732 startingPage "110" @default.
• W1998504732 abstract "Tigecycline is a promising therapeutic option against many current multidrug resistant pathogens. The aim of this retrospective study was to determine the clinical and microbiological outcomes of patients treated with tigecycline for serious infections caused by carbapenem-resistant Acinetobacter calcoaceticus Acinetobacter baumannii complex (Acb-complex). A retrospective study was conducted to define the patients who received tigecycline for carbapenem-resistant Acb-complex infections between 1 June, 2008 and 1 may, 2009. A total of 21 patients were eligible for the study. The median age of the patients was 48 years and 6 patients were female. Eighteen patients were treated with tigecycline for carbapenem-resistant Acb-complex as the sole microorganism while 3 received it for polymicrobial infections. All Acb-complex isolates were susceptible to tigecycline. The most common indication of tigecycline treatment was surgical-site infections (SSI) followed by ventilator associated pneumonia (VAP). Tigecycline was the sole antibiotic administered in 7 patients while concurrent antibiotics were used in 14 patients. The median duration of tigecycline therapy was 14days. Two patients died within 14 days of initiating treatment, representing an attributable mortality rate of 9.5% while 4 patients died within 30 days representing a crude mortality rate of 19.1%. Seventeen out of 21 patients had successful clinical outcomes, cure in 11 patients and improvement in 6. Fourteen of 21 patients had microbiological failure. Correlation between microbiological response with clinical outcome was poor. Clinical failure was more common in patients with VAP. Patients with bacteremia were more likely to have microbiological failure while microbiological outcome was better in patients with SSI. In this retrospective study, 81% (17 of 21) of the patients infected with carbapenem-resistant Acb-complex had a positive outcome under tigecycline therapy. However, these preliminary results should be evaluated cautiously in the absence of well-controlled studies." @default.
• W1998504732 created "2016-06-24" @default.
• W1998504732 creator A5024272638 @default.
• W1998504732 creator A5026831987 @default.
• W1998504732 creator A5033790181 @default.
• W1998504732 creator A5040576831 @default.
• W1998504732 creator A5043477953 @default.
• W1998504732 creator A5059194599 @default.
• W1998504732 date "2010-04-01" @default.
• W1998504732 modified "2023-09-26" @default.
• W1998504732 title "Clinical Experience with Tigecycline in the Treatment of Carbapenem-Resistant<i>Acinetobacter</i>Infections" @default.
• W1998504732 cites W2011770881 @default.
• W1998504732 cites W2023287527 @default.
• W1998504732 cites W2023302805 @default.
• W1998504732 cites W2044742253 @default.
• W1998504732 cites W2071150805 @default.
• W1998504732 cites W2073060575 @default.
• W1998504732 cites W2094914709 @default.
• W1998504732 cites W2111475878 @default.
• W1998504732 cites W2129734287 @default.
• W1998504732 cites W2130267127 @default.
• W1998504732 cites W2139881333 @default.
• W1998504732 cites W2141617342 @default.
• W1998504732 cites W2148134051 @default.
• W1998504732 cites W2159435953 @default.
• W1998504732 cites W4246477994 @default.
• W1998504732 doi "https://doi.org/10.1179/joc.2010.22.2.110" @default.
• W1998504732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20435570" @default.
• W1998504732 hasPublicationYear "2010" @default.
• W1998504732 type Work @default.
• W1998504732 sameAs 1998504732 @default.
• W1998504732 citedByCount "27" @default.
• W1998504732 countsByYear W19985047322012 @default.
• W1998504732 countsByYear W19985047322013 @default.
• W1998504732 countsByYear W19985047322014 @default.
• W1998504732 countsByYear W19985047322015 @default.
• W1998504732 countsByYear W19985047322016 @default.
• W1998504732 countsByYear W19985047322018 @default.
• W1998504732 countsByYear W19985047322019 @default.
• W1998504732 countsByYear W19985047322020 @default.
• W1998504732 countsByYear W19985047322023 @default.
• W1998504732 crossrefType "journal-article" @default.
• W1998504732 hasAuthorship W1998504732A5024272638 @default.
• W1998504732 hasAuthorship W1998504732A5026831987 @default.
• W1998504732 hasAuthorship W1998504732A5033790181 @default.
• W1998504732 hasAuthorship W1998504732A5040576831 @default.
• W1998504732 hasAuthorship W1998504732A5043477953 @default.
• W1998504732 hasAuthorship W1998504732A5059194599 @default.
• W1998504732 hasConcept C126322002 @default.
• W1998504732 hasConcept C141071460 @default.
• W1998504732 hasConcept C167135981 @default.
• W1998504732 hasConcept C2776315533 @default.
• W1998504732 hasConcept C2776685102 @default.
• W1998504732 hasConcept C2777027569 @default.
• W1998504732 hasConcept C2777184939 @default.
• W1998504732 hasConcept C2777637488 @default.
• W1998504732 hasConcept C2777914695 @default.
• W1998504732 hasConcept C2778523567 @default.
• W1998504732 hasConcept C2779443120 @default.
• W1998504732 hasConcept C501593827 @default.
• W1998504732 hasConcept C523546767 @default.
• W1998504732 hasConcept C54355233 @default.
• W1998504732 hasConcept C71924100 @default.
• W1998504732 hasConcept C86803240 @default.
• W1998504732 hasConcept C89423630 @default.
• W1998504732 hasConceptScore W1998504732C126322002 @default.
• W1998504732 hasConceptScore W1998504732C141071460 @default.
• W1998504732 hasConceptScore W1998504732C167135981 @default.
• W1998504732 hasConceptScore W1998504732C2776315533 @default.
• W1998504732 hasConceptScore W1998504732C2776685102 @default.
• W1998504732 hasConceptScore W1998504732C2777027569 @default.
• W1998504732 hasConceptScore W1998504732C2777184939 @default.
• W1998504732 hasConceptScore W1998504732C2777637488 @default.
• W1998504732 hasConceptScore W1998504732C2777914695 @default.
• W1998504732 hasConceptScore W1998504732C2778523567 @default.
• W1998504732 hasConceptScore W1998504732C2779443120 @default.
• W1998504732 hasConceptScore W1998504732C501593827 @default.
• W1998504732 hasConceptScore W1998504732C523546767 @default.
• W1998504732 hasConceptScore W1998504732C54355233 @default.
• W1998504732 hasConceptScore W1998504732C71924100 @default.
• W1998504732 hasConceptScore W1998504732C86803240 @default.
• W1998504732 hasConceptScore W1998504732C89423630 @default.
• W1998504732 hasIssue "2" @default.
• W1998504732 hasLocation W19985047321 @default.
• W1998504732 hasLocation W19985047322 @default.
• W1998504732 hasOpenAccess W1998504732 @default.
• W1998504732 hasPrimaryLocation W19985047321 @default.
• W1998504732 hasRelatedWork W1132968485 @default.
• W1998504732 hasRelatedWork W2038023577 @default.
• W1998504732 hasRelatedWork W2061481058 @default.
• W1998504732 hasRelatedWork W2064255498 @default.
• W1998504732 hasRelatedWork W2077029129 @default.
• W1998504732 hasRelatedWork W2148626913 @default.
• W1998504732 hasRelatedWork W2404220912 @default.
• W1998504732 hasRelatedWork W2725279732 @default.
• W1998504732 hasRelatedWork W2984631324 @default.
• W1998504732 hasRelatedWork W2988098851 @default.
• W1998504732 hasVolume "22" @default.

• next